Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | HERO phase III trial in advanced prostate cancer

Neal Shore • 21 May 2020
ASCO 2020
Genitourinary Cancer Prostate Cancer Leuprolide Relugolix
HERO

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, USA, discusses data coming from the HERO phase III study (NCT03085095) comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Neal Shore

0:56
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
Neal Shore • 26 Jan 2024
0:51
OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS
Neal Shore • 26 Jan 2024
0:44
PROpel: gene-by-gene efficacy of olaparib and abiraterone in mCRPC
Neal Shore • 26 Jan 2024
0:39
TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPC
Neal Shore • 26 Jan 2024

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals